OraSure Technologies Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OraSure Technologies stock.
View analyst ratings for OraSure Technologies or view top-rated stocks.

Wall Street analysts have given OraSure Technologies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OraSure Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

OraSure Technologies saw a decline in short interest in August. As of August 13th, there was short interest totaling 4,120,000 shares, a decline of 25.1% from the July 29th total of 5,500,000 shares. Based on an average daily volume of 890,000 shares, the days-to-cover ratio is currently 4.6 days. Currently, 5.8% of the company's shares are sold short.
View OraSure Technologies' Short Interest.

OraSure Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for OraSure Technologies.

OraSure Technologies, Inc. (NASDAQ:OSUR) released its quarterly earnings results on Tuesday, August, 3rd. The medical instruments supplier reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.06. The medical instruments supplier had revenue of $57.61 million for the quarter, compared to analysts' expectations of $56.50 million. OraSure Technologies had a trailing twelve-month return on equity of 1.33% and a net margin of 2.34%.
View OraSure Technologies' earnings history.

OraSure Technologies' stock was trading at $5.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OSUR shares have increased by 126.8% and is now trading at $13.38.
View which stocks have been most impacted by COVID-19.

OraSure Technologies updated its third quarter 2021 earnings guidance on Tuesday, August, 17th. The company provided EPS guidance of for the period. The company issued revenue guidance of $45 million-$50 million, compared to the consensus revenue estimate of $67.88 million.

3 brokers have issued twelve-month price targets for OraSure Technologies' stock. Their forecasts range from $12.50 to $15.00. On average, they anticipate OraSure Technologies' share price to reach $14.17 in the next twelve months. This suggests a possible upside of 5.9% from the stock's current price.
View analysts' price targets for OraSure Technologies or view top-rated stocks among Wall Street analysts.

2 employees have rated OraSure Technologies CEO Stephen Tang on Glassdoor.com. Stephen Tang has an approval rating of 100% among OraSure Technologies' employees. This puts Stephen Tang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to OraSure Technologies include Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), STAAR Surgical (STAA), Quidel (QDEL), ICU Medical (ICUI), Neogen (NEOG), Merit Medical Systems (MMSI), Haemonetics (HAE), Atrion (ATRI), Cerus (CERS), Meridian Bioscience (VIVO), Antares Pharma (ATRS) and Anika Therapeutics (ANIK).
View all of OSUR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OraSure Technologies investors own include Merit Medical Systems (MMSI), Citigroup (C), Energy Transfer (ET), XOMA (XOMA), Overstock.com (OSTK), Ford Motor (F), Pfizer (PFE), Abbott Laboratories (ABT), Advanced Micro Devices (AMD) and Activision Blizzard (ATVI).

OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."

OraSure Technologies' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (19.53%), Bank of America Corp DE (7.33%), Bank of America Corp DE (7.33%), Vanguard Group Inc. (6.61%), American Capital Management Inc. (5.08%) and State Street Corp (4.55%).
View institutional ownership trends for OraSure Technologies.

OSUR stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Prudential Financial Inc., Vanguard Group Inc., Victory Capital Management Inc., Wells Fargo & Company MN, Balyasny Asset Management LLC, Goldman Sachs Group Inc., and AQR Capital Management LLC.
View insider buying and selling activity for OraSure Technologies or view top insider-selling stocks.

OSUR stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Systematic Financial Management LP, Morgan Stanley, Morgan Stanley, Bank of America Corp DE, Bank of America Corp DE, State Street Corp, and AXA S.A..
View insider buying and selling activity for OraSure Technologies or or view top insider-buying stocks.

Shares of OSUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OSUR stock can currently be purchased for approximately $13.38.

OraSure Technologies has a market capitalization of $963.48 million and generates $171.72 million in revenue each year. The medical instruments supplier earns $-14,920,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

OraSure Technologies employs 570 workers across the globe.

The official website for OraSure Technologies is www.orasure.com.

OraSure Technologies is headquartered at 220 EAST FIRST STREET, BETHLEHEM PA, 18015.

OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The medical instruments supplier can be reached via phone at (610) 882-1820 or via email at [email protected].